Inotiv, Inc. (NASDAQ:NOTVQ) — Market Cap & Net Worth
Market Cap & Net Worth: Inotiv, Inc. (NOTVQ)
Inotiv, Inc. (NASDAQ:NOTVQ) has a market capitalization of $390.42K ($390.42K) as of August 23, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31084 globally and #6252 in its home market, demonstrating a -34.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inotiv, Inc.'s stock price $0.01 by its total outstanding shares 35172908 (35.17 Million). See Inotiv, Inc. balance sheet quality to understand what proportion of total assets are financed by equity.
Inotiv, Inc. Market Cap History: 2026 to 2026
Inotiv, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $390.42K to $390.42K (0.00% CAGR). Also see total assets of Inotiv, Inc. for a full breakdown of the balance sheet.
Inotiv, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inotiv, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check NOTVQ share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NOTVQ by Market Capitalization
Companies near Inotiv, Inc. in the global market cap rankings as of August 23, 2026. Also see Inotiv, Inc. (NOTVQ) cash flow conversion for how efficiently the company converts equity into cash flow.
Key companies related to Inotiv, Inc. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #159 globally with a market cap of $154.58 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #462 globally with a market cap of $58.94 Billion USD ( CN¥402.80 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #602 globally with a market cap of $45.89 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $629.27 |
| #159 | Danaher Corporation | NYSE:DHR | $154.58 Billion | $218.85 |
| #462 | WuXi AppTec Co Ltd | SHG:603259 | $58.94 Billion | CN¥162.86 |
| #602 | Natera Inc | NASDAQ:NTRA | $45.89 Billion | $332.03 |
Inotiv, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Inotiv, Inc.'s market cap moved from $390.42K to $ 390.42K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $390.42K | -- |
End of Day Market Cap According to Different Sources
On Aug 23rd, 2026 the market cap of Inotiv, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $390.42K USD |
| MoneyControl | $390.42K USD |
| MarketWatch | $390.42K USD |
| marketcap.company | $390.42K USD |
| Reuters | $390.42K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inotiv, Inc.
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more